2012 Guidelines of the Taiwan Society of Cardiology (TSOC) for the diagnosis and treatment of heart failure

Acta Cardiologica Sinica

Volumn 28, Issue 2, 2012, Pages 161-195

  Wang, Chun Chieh ^a   Chen, Jyh Hong ^b   Yu, Wen Chung ^c   Cheng, Jun Jack ^d   Yin, Wei Hsian ^e   Wu, Chau Chung ^f   Li, Ai Hsien ^g   Lin, Wei Shiang ^h   Chen, Po Sheng ^b   Ueng, Kwo Chang ⁱ   Huang, Jin Long ^j   Tsai, Feng Chun ^a   Wang, Chao Hung ^k   Fu, Tieh Cheng ^k   Liu, Min Hui ^k   Chen, Pey Rong ^f   Pai, Hsi Yen ^l   Cherng, Wen Jin ^k  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^h NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l FENG YUAN HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CHLOROTHIAZIDE; CREATININE; ELECTROLYTE; ENALAPRIL; EPLERENONE; FOSINOPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; VALSARTAN;

ANGIOCARDIOGRAPHY; ASCITES; BLOOD CELL COUNT; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; CENTRAL VENOUS PRESSURE; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIURETIC THERAPY; DYSPNEA; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; EXERCISE TOLERANCE; FATIGUE; FLUID RETENTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE BIOPSY; HEPATOMEGALY; HOLTER MONITORING; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LUNG FUNCTION TEST; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PROGNOSIS; RADIOISOTOPE VENTRICULOGRAPHY; REVIEW; STRESS ECHOCARDIOGRAPHY; SYMPTOMATOLOGY; TACHYCARDIA; TAIWAN; THORAX RADIOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; URINALYSIS;

EID: 84865461179     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001;104:2996-3007. (Pubitemid 33139116)
3. Hunt SA, AbrahamWT, Chin MH, et al. ACC/AHA2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology/American Heart the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; endorsed by the Heart Rhythm Society. Circulation 2005;112:1825-52. (Pubitemid 41368159)
4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
5. Cleland JGF, Erdmann E, Ferrari R, et al. Guidelines for the diagnosis of heart failure. the task force on heart failure of the European Society of Cardiology. Eur Heart J 1995;16:741-51.
6. Remme WJ, Cleland JGF, Dargie H, et al. The treatment of heart failure. the task force of the working group on heart failure of the European Society of Cardiology. Eur Heart J 1997;18:736-53.
7. Remme WJ, Swedberg K, Cleland J, et al. Guidelines for the diagnosis and treatment of chronic heart failure. task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001;22:1527-60.
8. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416. (Pubitemid 40283098)
9. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007;28:2256-95. (Pubitemid 47428944)
10. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
11. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
12. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194.
13. Mant J, Al-Mohammad A, Swain S, et al. Management of chronic heart failure in adults: synopsis of the National Institute for Health and Clinical Excellence Guideline. Ann Intern Med 2011;155:252-9.
14. Huang CH, Chien KL, Chen WJ, et al. Impact of heart failure and left ventricular function on long-term survival - report of a community-based cohort study in Taiwan. Eur J Heart Fail 2007;9:587-93. (Pubitemid 46702825)
15. Ikram H. Identifying the patient with heart failure. J Int Med Res 1995;23:139-53.
16. Madhok V, Falk G, Rogers A, et al. The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review. BMC Fam Pract 2008;9:56.
17. Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335-9. (Pubitemid 27237032)
18. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50. (Pubitemid 47614269)
19. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson 2004;6:727-65. (Pubitemid 40041279)
20. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/ SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006;48:1475-97.
21. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-95. (Pubitemid 13019226)
22. Fox KF, Cowie MR,Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001;22:228-36. (Pubitemid 32622473)
23. Arques S, Ambrosi P, Gelisse R, et al. Prevalence of angiographic coronary artery disease in patients hospitalized for acute diastolic heart failure without clinical and electrocardiographic evidence of myocardial ischemia on admission. Am J Cardiol 2004;94:133-5. (Pubitemid 38813471)
24. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007;28:3076-93. (Pubitemid 350262258)
25. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
26. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
27. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
28. Cohn JN, Tognoni G. The Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75. (Pubitemid 33126822)
29. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-ezyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6. (Pubitemid 37093917)
30. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60. (Pubitemid 35247704)
31. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
32. GIGGI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
33. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23. (Pubitemid 14035089)
34. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VACooperative Studies Group. Circulation 1993;87:V140-8.
35. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
36. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009;84:718-29.
37. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
39. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55. (Pubitemid 26152713)
40. Ventura HO. Benefits of inpatient initiation of beta-blockers. Am Heart J 2004;148:944-50.
41. Peterson PN, Rumsfeld JS, Liang L, et al. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes 2010;3;309-15.
42. Howlett JG, McKelvie RS, Costigan J, et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010;26:185-202.
43. Chinese Society of Cardiology of Chinese Medical Association. Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:1076-95.
44. Hu H, Jui HY, Hu FC, et al. Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. J Formos Med Assoc 2007;106:641-8. (Pubitemid 47377255)
45. ICSI Health Care Guideline: Heart failure in adults 11th Edition/December 2009.
46. National Institute for Health and Clinical Excellence: NICE clinical guideline 108 for chronic heart failure: management of chronic heart failure in adults in primary and secondary care. Issue date: August 2010.
47. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
48. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
49. Verma A, Bulwer B, Dhawan I, et al. Aldosterone receptor antagonist and heart failure following acute myocardial infarction. Acta Cardiol Sin 2010;26:203-15.
50. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
51. Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther 2005;19:301-6. (Pubitemid 41778811)
52. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
53. Hood WB Jr, Dans AL, Guyatt GH, et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004;10:155-64. (Pubitemid 38858077)
54. Wang MT, Li IH, Lee WJ, et al. Exposure to sennoside-digoxin interaction and risk of digoxin toxicity: a population-based nested case-control study. Eur J Heart Fail 2011;13:1238-43.
55. Wang MT, Su CY, Chan AL, et al. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. Br J Clin Pharmacol 2010;70:258-67.
56. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G. (Pubitemid 41338074)
57. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003. (Pubitemid 36315544)
58. Galley HF. Renal-dose dopamine: will the message now get through? Lancet 2000;356:2112-3. (Pubitemid 32047940)
59. Gilbert EM, Hershberger RE, Wiechmann RJ, et al. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995;108:1524-32.
60. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141-9. (Pubitemid 34017432)
61. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91. (Pubitemid 46707842)
62. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-58.
63. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10. (Pubitemid 43012109)
64. Huang SC, Chi NH, Chen CA, et al. Left ventricular assist for pediatric patients with dilated cardiomyopathy using the Medos VAD cannula and a centrifugal pump. Artif Organs 2009;33:1032-7.
65. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham Study. JAMA 1983;250:2942-6. (Pubitemid 14202371)
66. Witt BJ, Gami AS, Ballman KV, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489-96. (Pubitemid 47176922)
67. Lip GY, Gibbs CR. Does heart failure confers a hypercoagulable state? Virchow's Triad Revisited. J Am Coll Cardiol 1999;33:1424-6.
68. Dotsenko O, KakkarW. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J Thromb Haemost 2007;5:224-31. (Pubitemid 46139441)
69. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64. (Pubitemid 38900496)
70. Massie BM, Krol WF, Ammon SE, et al. The warfarin and antiplatelet therapy in heart failure trial (WATCH): rationale, design and baseline patient characteristics. J Card Fail 2004;10:101-12. (Pubitemid 38858069)
71. Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. Eur J Heart Fail 2006;8:428-32. (Pubitemid 43832171)
72. Pullicino P, Thompson JL, Barton B, et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006;12:39-46. (Pubitemid 43267750)
73. Lin LJ, Cheng MH, Lee CH, et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-A nationwide descriptive study in Taiwan. Clin Ther 2008;30:1726-36.
74. Yu HY, Liu CH, Chen YS, et al. Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanses patients receiving vitaminK antagonist after mechanical valve replacement. J Formos Med Assoc 2005;104: 236-43. (Pubitemid 44473668)
75. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
76. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
77. Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-40. (Pubitemid 19222034)
78. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of betablockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165-71. (Pubitemid 43076435)
79. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574-9. (Pubitemid 29001197)
80. Dronedarone prescribing information. www.multaq.com revised 12/2011.
81. Rubenfeld GD, McNamara-Aslin E, Rubinson L. The pulmonary artery catheter, 1967-2007: rest in peace? JAMA 2007;298:458-61. (Pubitemid 47124068)
82. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-HF) study. Circulation 2005;111:2454-60. (Pubitemid 40696133)
83. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-7. (Pubitemid 37443288)
84. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-8. (Pubitemid 47343897)
85. Bellone A, Vettorello M, Monari A, et al. Noninvasive pressure support ventilation vs. continuous positive airway pressure in acute hypercapnic pulmonary edema. Intensive Care Med 2005;31:807-11. (Pubitemid 40897535)
86. L'Her E, Duquesne F, Girou E, et al. Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema. Intensive Care Med 2004;30:882-8. (Pubitemid 38639481)
87. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-6. (Pubitemid 41713589)
88. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003;362:777-81. (Pubitemid 37093918)
89. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. I-PRESERVE Investigators. N Engl J Med 2008;359:2456-67.
90. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9. (Pubitemid 44088349)
91. Piller LB, Baraniuk S, Simpson LM, et al. ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2011;124:1811-8.
92. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45. (Pubitemid 44453578)
93. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-8.
94. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77. (Pubitemid 47243795)
95. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Areport of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713. (Pubitemid 37383745)
96. Tseng CH. Clinical features of heart failure hospitalization in younger and elderly patients in Taiwan. Eur J Clin Invest 2011;41:597-604.
97. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 2006;27:2682-8. (Pubitemid 44729869)
98. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003;289:2685-94. (Pubitemid 37430139)
99. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:e350-408.
100. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
101. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49. (Pubitemid 40517094)
102. Wang CL, Wu CT, Yeh YH, et al. New approaches to evaluate mechanical dyssynchrony - potential usefulness in predicting response to cardiac resynchronization therapy. Acta Cardiol Sin 2010;26:142-50.
103. Tsai CT, Huang SK, Lin JL, et al. Taiwan ICD Registry Investigators. Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study. Pacing Clin Electrophysiol 2003;26:2083-90. (Pubitemid 37433674)
104. WuMY, Lin PJ, LeeMY, et al. Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and midterm survival. Resuscitation 2010;81:1111-6.
105. Chen SW, Tsai FC, Tsai FC, et al. Selective treatment algorithm for mitral valve annuloplasty in non-ischemic functional mitral regurgitation. J Card Fail 2009;15:341-6.
106. Wei J, Chang CY, Chuang YC, et al. Updates in heart transplantation. Transplant Proc 2008;40:2594-6.
107. ACSM's Guidelines for Exercise Testing and Prescription. 8th ed.,2010Walter R Thompson Ph.D ed LWW.
108. Cardiovascular and Pulmonary Physical Therapy An Evidence-Based Approach. 2nd ed 2011, William E. DeTurk & Lawrence P.Cahalin.
109. Piña IL, Apstein CS, Balady GJ. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003;107:1210-25. (Pubitemid 36297217)
110. Heart failure exercise/activity guidelines - exercise. http://my.clevelandclinic.org/disorders/heart-failure/hic-heart-failure- exercise-activity-guidelines.aspx.
111. Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008;168:316-24. (Pubitemid 351281679)
112. Juilliére Y, Jourdain P, Roncalli J, et al. Therapeutic education for cardiac failure patients: the I-care programme. Arch Mal Coeur Vaiss 2005;98:300-7.
113. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005;111:179-85. (Pubitemid 40139729)
114. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
115. Stromberg A. The crucial role of patient education in heart failure. Eur J Heart Fail 2005;7:363-9. (Pubitemid 40253569)
116. Boyde M, Tuckett A, Peters R, et al. Learning style and learning needs of heart failure patients (The Need2Know-HF patient study). Eur J Cardiovasc Nurs 2009;8:316-22.
117. Caldwell MA, Peters KJ, Dracup KA. A simplified education program improves knowledge, self-care behavior, and disease severity in heart failure patients in rural settings. Am Heart J2005;150:983.
118. Holst M, Willenheimer R, Mårtensson J, et al. Telephone follow- up of self-care behaviour after a single session education of patients with heart failure in primary health care. Eur J Cardiovasc Nurs 2007;6:153-9. (Pubitemid 46734779)
119. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810-9. (Pubitemid 39099578)
120. Phillips CO, Singa RM, Rubin HR, et al. Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse led heart failure clinics. A metaregression analysis. Eur J Heart Fail 2005;7:333-41. (Pubitemid 40249525)
121. Neily JB, Toto KH, Gardner EB, et al. Potential contributing factors to noncompliance with dietary sodium restriction in patients with heart failure. Am Heart J 2002;143:29-33. (Pubitemid 34056372)
122. Wang CS, Wang ST, Lai CT, et al. Reducing major cause - specific hospitalization rates and shortening hospital stays after influenza vaccination. Clin Infect Dis 2004;39:1604-10.
123. Tung HH, Chen HH, Yin WH, et al. Self care behavior in patients with heart failure in Taiwan. Eur J Cardiovasc Nurs 2012;11:175-82.
124. Meltzer JS, Moitra VK. The nutritional and metabolic support of heart failure in the intensive care unit. Curr Opin Clin Nutr Metab Care 2008;11:140-6. (Pubitemid 351323175)
125. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24.
126. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
127. Chobanian AV, Bakris GL, Black HR, et al. National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
128. Alice H, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations revision 2006: Ascientific statement from the American heart association nutrition committee. Circulation 2006;114:82-96. (Pubitemid 44305278)
129. American diabetes association position statement: standards of medical care in diabetes-2011. Diabetes Care 2011;34:S11-61.
130. Arcand J, Ivanov J, Sasson A, et al. Ahigh-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. Am J Clin Nutr 2011;93:332-7.
131. Mahan LK, Escott-Stump S. Krause's food, nutrition, & diet therapy. 12th ed. Missouri: Saunders Elsevier, 2008. ISBN 978-1-4160-3401-8, page 884-98.
132. Riegel B, Moser DK, Anker SD, et al. Promoting self-care in persons with heart failure: Ascientific statement from the American Heart Association. Circulation 2009;120:1141-63.
133. Springer J, Filippatos G, Akashi YJ, et al. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 2006;21:229-33. (Pubitemid 44315088)
134. Dunn SP, Bleske B, Dorsch M, et al. Nutrition and heart failure: impact of drug therapies and management strategies. Nutr Clin Pract 2009;24:60-75.
135. Morley JE. Calories and cachexia. Curr Opin Clin Nutr Metab Care 2009;12:607-10.
136. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.
137. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating longchain-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study. Ann Intern Med 2011;155:160-70.
138. Miján-de-la-Torre A. Recent insights on chronic heart failure, cachexia and nutrition. Curr Opin Clin Nutr Metab Care 2009;12:251-7.
139. Adler ED, Goldfinger JZ, Kalman J, et al. Palliative care in the treatment of advanced heart failure. Circulation 2009;120:2597-606.
140. Zambroski CH. Hospice as an alternative model of care for older patients with end-stage heart failure. J Cardiovasc Nurs 2004;19:76-83.
141. Stuart B, Alexander C, Arenella C, et al. Medical guidelines for determining prognosis in selected non-cancer diseases. 2nd ed. Arlington, VA: National Hospice Organization; 1996.
142. Davis MP, Albert NM, Young JB. Palliation of heart failure. Am J Hosp Palliat Care 2005; 22:211-22. (Pubitemid 40745020)